Lotus joins the Sapien and CoreValve/Evolut families of TAVR devices in that indication. It is unique in being repositionable and retrievable after full deployment
Lotus joins the Sapien and CoreValve/Evolut families of TAVR devices in that indication. It is unique in being repositionable and retrievable after full deployment
A fourth competitor in the TAVR space, the JenaValve, is in a pivotal study
Aortic stenosis is narrowing of the main valve , impeding blood flow circulation from the heart to the aorta.
More than 1.5 million of people live in US with aortic stenosis, and the current, standard treatment is surgical replacement of the valve, through open heart surgery.
The risks of open heart surgery precludes this treatment for about 30% of patients, who are deemed to be ” high risk candidates” for surgery, due to age, or preexisting conditions: advanced kidney failure, emphysema, home Oxygen dependency, severe heart failure, advanced malignancy. The risk of surgery and recovery is so high, that outweighs the benefit .
These patients, with severe Aortic stenosis, (AS), without surgery, have a high mortality within 2 years of diagnosis and poor quality of life ; their prognosis is worse than most advanced, metastatic cancers.
These patients, with severe Aortic stenosis, (AS), without surgery, have a high mortality within 2 years of diagnosis and poor quality of life ; their prognosis is worse than most advanced, metastatic cancers.
TAVR, or – trans catheter aortic valve replacement, became lately a great alternative of surgery.
TAVR means replacing the valve, minimally invasive, without open heart , with a catheter inserted through the groin which delivers and deploys the valve; almost like an angiogram and stent placement. There is no surgical risk and the procedure carries much less recovery time, ( 1-2 days) vs (5-6 days). The procedure is performed by a cardiologist, in the cardiac catheterization laboratory, lasting a couple of hours.